Animal studies have demonstrated that in addition to inhibiting growth hormone (GH) secretion octreotide inhibits in a direct manner hepatic or peripheral insulin-like growth factor I (IGF-I) generation. To test this hypothesis in humans we studied ten GH-deficient patients with frequent blood sampling during 38 h on two occasions. Regular GH therapy was discontinued 72 h prior to each study period. At the start of each study a subcutaneous (sc) injection of GH (3 IU/m2) was given (at 18.00 h). In a single-blinded crossover design, patients received a continuous sc infusion of either octerotide (200 \g=m\g/24h) or placebo (saline). The pharmacokinetics of GH were similar on the two occasions. The area under the curve\m=+-\semof serum GH was 142.5\m=+-\53.6 \ g=m\ g\ m=. \ l \ m=-\ 1\ m=. \ h\ m=-\ 1 (octreotide) and 144.8\m=+-\41.8 \ g=m\ g\ m=. \ l \ m=-\ 1\ m=. \ h\ m=-\ 1(placebo), (p=0.73); Cmax (\g=m\g/l) was 12.5\m=+-\1.47(octreotide) and 12.8\m=+-\1.42(placebo) (p=0.83), and Tmax (h) was 6.1\m=+-\0.97(octreotide) and 5.2\m=+-\0.65(placebo) (p=0.49). Growth hormone administration was associated with an increase in serum IGF-I (\g=m\g/l), which was identical during the two studies, from 85.3\m=+-\19.4to 174.25\m=+-\30.3for octreotide and from 97.0\m=+-\26.4to 158.8\m=+-\28.2for placebo. Mean IGF-I levels (\g=m\g/l) were 138.2\m=+-\25.1(octreotide) and 134.5\m=+-\28.6 (placebo) (p=0.78). Similarly, the increase in IGF binding protein 3 (IGFBP-3) levels was identical. Mean IGFBP-3 levels (\g=m\g/l) were 2303\m=+-\323(octreotide) and 2200\m=+-\361(placebo) (p=0.25). Mean insulin levels were significantly lower during octreotide treatment (39.9 \m=+-\17.9mU/l) than during placebo (59.7\m=+-\17.8mU/l) (p<0.05). Mean blood glucose levels were elevated significantly during octreotide infusion (5.98 \m=+-\0.23mmol/l for octreotide and 5.07\m=+-\0.16mmol/l for placebo; p=0.001). Glucagon levels decreased non-significantly (p=0.07) and IGFBP-1 levels tended to increase during infusion of octreotide although not significantly (p=0.41). Levels of the lipid intermediates were identical on the two occasions. Alanine and lactate levels were significantly increased during octreotide infusion. Mean levels of blood alanine (\g=m\mol/l) were 470.8\m=+-\24.2(octreotide) and 360.1\m=+-\17.8 (placebo) (p<0.02). Mean levels of blood lactate were 1038\m=+-\81.0(octreotide) and 894.4\m=+-\73.8 (placebo) (p<0.04). We conclude that short-term continuous sc infusion of octreotide has no direct effect on the generation of IGF-I or the pharmacokinetics of exogenous GH in GH-deficient man.
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The second of the two antibodies against IGF-I was labeled with Europium (Delfia, Wallac, Finland). The interassay coefficient of variation (cv) in samples was < 10%, the intra-assay cv in standards as well as samples was < 5% and the lower detection limit was <2.5 ng/1. The IGFBP-3 was measured by RIA using a polyclonal antibody against the acid-stable binding subunit (IGFBP-3/)) as originally described by Blum et al. (17) . The intra-assay cv in standards and samples was <5%, the interassay cv was <7.5% and the lower detection limit was <1 yg/l; normal range (adults) >2100 yg/l. Serum IGFBP-1 was measured by an immunoenzymometric kit using two monoclonal anti¬ bodies. The intra-assay cv was < 5%, the interassay cv was < 7.5% and the lower detection limit was 0. 4 (Fig. 2, lower panel) (Fig. 3, upper panel) Blood glucose (Fig. 3, middle panel) . Blood (Fig. 3, lower panel) (14, 15) . This may be due to differences between species. Another explanation may be that the reduced serum IGF-I levels in these studies could be due to a reduction of IGF-I binding protein levels induced by octreotide. Only in a small number of patients with acromegaly treated with octreotide have the IGF-I levels been reported to be relatively more reduced than GH levels (4, 5, 12) . The most common finding is that IGF-I levels correlate with GH levels during octreotide treatment (7, 9) . The IGF-I levels have even been reported to be unaltered or increased during octreotide treatment, despite reduced GH levels (11) . In the above studies of patients with acromegaly and animals (hypox rats), octreotide was administered for a longer period than in our study, and its impact on IGF-I and IGFBP-3 levels may require more prolonged administration of the drug.
As nutrition affects IGF-I levels (29) (iv) elevated glucose levels but unaltered NEFA; (v) elevated levels of alanine and lactate. Our short-term study thus failed to detect a GHindependent effect of octreotide on IGF-I generation in humans.
